|
188Re-marked Ior C5 MAb in persistent or relapsing ovary epithelial cancer, phase I. |
2010-12-27 |
CIM |
|
Nimotuzumab in the treatment of patients with acute respiratory difficulty syndrome (ARDS) |
03/03/2023 |
CIM |
|
Vaccine HER1 / VSSP for prostate cancer, head and neck carcinoma and advanced colon cancer . Phase I |
03/11/2017 |
CIM |
|
14F7 in chronic B-cell lymphoproliferative syndrome |
07/03/2018 |
CIM |
|
NGcGM3/VSSP and nimotuzumab in patients with triple negative breast cancer |
12/10/2016 |
CIM |
|
Itolizumab for Relapsing Remitting Multiple Sclerosis |
22/05/2015 |
CIM |
|
Itolizumab for Moderate-to-Severe Psoriasis-phase 3 |
08/10/2015 |
CIM |
|
Racotumomab-alum for recurrent platimun-sensitive epithelial ovarian cancer |
08/07/2015 |
CIM |
|
Racotumomab-alum cancer vaccine for solid tumors in pediatric patients |
15/12/2015 |
CIM |
|
CIMAbior® in CD20-positive B-cell Non-Hodgkin Lymphoma |
05/09/2017 |
CIM |
|
Vaxira as adjuvant treatment for non-small cell lung cancer |
15/12/2015 |
CIM |
|
Dose scale-up and cohort expansion with the therapeutic mAb 14F7 |
04/12/2015 |
CIM |
|
NeuroEPO in patients with Mild-Moderate Alzheimer's disease |
01/02/2017 |
CIM |
|
Phase I/II trial with the mutein no alfa of IL-2 |
03/02/2017 |
CIM |
|
Combined NGcGM3/VSSP and Nimotuzumab in advanced non-small cell lung cancer (NSCLC) |
30/04/2018 |
CIM |
|
NGcGM3/VSSP in patients with metastatic hormone-receptor positive and HER2 negative breast cancer |
28/11/2016 |
CIM |
|
Nimotuzumab cold kit for the immunodiagnosis of solid tumors |
05/10/2018 |
CIM |
|
CIMAvax-EGF® in metastatic asymptomatic or mildly symptomatic Castration Resistant Prostate Cancer patients. Phase II-III Clinical Trial |
17/10/2018 |
CIM |
|
VSSP in metastasic renal cell carcinoma |
08/08/2018 |
CIM |
|
Racotumomab vaccine- Lung Cancer- Adults-predictors of response - Exploratory |
09/07/2018 |
CIM |
